Equities Analysts Offer Predictions for SRPT Q1 Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – HC Wainwright increased their Q1 2025 earnings per share estimates for Sarepta Therapeutics in a research note issued to investors on Monday, December 2nd. HC Wainwright analyst M. Kapoor now anticipates that the biotechnology company will post earnings per share of $2.35 for the quarter, up from their prior forecast of $2.32. HC Wainwright has a “Sell” rating and a $75.00 price target on the stock. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.16 per share. HC Wainwright also issued estimates for Sarepta Therapeutics’ Q2 2025 earnings at $2.64 EPS, Q3 2025 earnings at $2.73 EPS, Q4 2025 earnings at $2.84 EPS and FY2025 earnings at $10.54 EPS.

SRPT has been the subject of a number of other research reports. William Blair raised shares of Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. StockNews.com cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and upped their target price for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. Evercore ISI lowered their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $182.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $175.55.

Sarepta Therapeutics Stock Up 0.4 %

NASDAQ:SRPT opened at $126.53 on Tuesday. The company’s 50-day simple moving average is $122.57 and its 200-day simple moving average is $131.40. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics has a fifty-two week low of $83.97 and a fifty-two week high of $173.25. The stock has a market capitalization of $12.09 billion, a P/E ratio of 100.81 and a beta of 0.77.

Hedge Funds Weigh In On Sarepta Therapeutics

Institutional investors have recently made changes to their positions in the company. Tidal Investments LLC boosted its holdings in Sarepta Therapeutics by 91.2% during the third quarter. Tidal Investments LLC now owns 5,634 shares of the biotechnology company’s stock worth $704,000 after buying an additional 2,688 shares in the last quarter. World Investment Advisors LLC acquired a new position in shares of Sarepta Therapeutics in the third quarter worth about $2,418,000. Sunbelt Securities Inc. boosted its stake in shares of Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 232 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Sarepta Therapeutics by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after acquiring an additional 44,306 shares during the period. Finally, M&T Bank Corp increased its stake in shares of Sarepta Therapeutics by 8.5% in the 3rd quarter. M&T Bank Corp now owns 4,462 shares of the biotechnology company’s stock valued at $558,000 after purchasing an additional 349 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.